Table 1 Individual characteristics, tumour characteristics, treatment regimens and mortality figures for the population of women diagnosed with BC in Scotland (1997 to 2016) by age group

NHS Region of Scotland

 North

3,639 (25%)

9,288 (26%)

5,665 (26%)

18,592 (26%)

 South East

4,020 (28%)

9,769 (27%)

6,044 (28%)

19,833 (28%)

 West

6,720 (47%)

16,535 (47%)

10,104 (46%)

33,359 (46%)

Year of diagnosis

 1997–2001

3,324 (23%)

7,741 (22%)

5,239 (24%)

16,304 (23%)

 2002–2006

3,543 (25%)

8,319 (23%)

5,427 (25%)

17,289 (24%)

 2007–2011

3,739 (26%)

9,473 (27%)

5,467 (25%)

18,679 (26%)

 2012–2016

3,773 (26%)

10,059 (28%)

5,680 (26%)

19,512 (27%)

SIMD quintile

 Least deprived

3,218 (23%)

7,570 (21%)

4,101 (19%)

14,889 (21%)

 4

3,080 (21%)

7,594 (21%)

4,252 (20%)

14,926 (21%)

 3

2,878 (20%)

7,387 (21%)

4,593 (21%)

14,858 (20%)

 2

2,726 (19%)

6,803 (19%)

4,729 (21%)

14,258 (20%)

 Most deprived

2,477 (17%)

6,238 (18%)

4,138 (19%)

12,853 (18%)

Charlson Index, mean (SD)

0.02 (0.20)

0.05 (0.26)

0.11 (0.39)

0.06 (0.30)

No. comorbidities∆

 0

14,157 (99%)

34,263 (96%)

19,770 (91%)

68,190 (95%)

 1

164 (1%)

1,096 (3%)

1,691 (8%)

2,951 (4%)

 2 or more

58 (0%)

233 (1%)

352 (1%)

643 (1%)

TNM stage

 I

3,851 (27%)

15,576 (44%)

4,682 (22%)

24,109 (34%)

 II

6,111 (42%)

11,875 (33%)

7,256 (33%)

25,242 (35%)

 III

2,573 (18%)

4,221 (12%)

3,540 (16%)

10,334 (14%)

 IV

601 (4%)

1,398 (4%)

1,612 (7%)

3,611 (5%)

 Unknown

1,243 (9%)

2,522 (7%)

4,723 (22%)

8,488 (12%)

Tumour grade

 Grade I

1,196 (8%)

5,625 (16%)

1,863 (8%)

8,684 (12%)

 Grade II

5,012 (35%)

15,063 (42%)

7,902 (36%)

27,977 (39%)

 Grade III

6,658 (46%)

11,237 (32%)

5,590 (26%)

23,485 (33%)

 Unknown

1,513 (11%)

3,667 (10%)

6,458 (30%)

11,638 (16%)

Tumour size (in cm)

 Less than 10 mm

1,108 (8%)

5,543 (16%)

1,016 (5%)

7,667 (11%)

 10 to 20 mm

5,034 (35%)

14,571 (41%)

4,698 (22%)

24,303 (34%)

 More than 20 mm

6,164 (43%)

11,014 (31%)

6,404 (29%)

23,582 (33%)

 Unknown

2,073 (14%)

4,464 (12%)

9,695 (44%)

16,232 (22%)

Positive nodal status?

 Yes

6,216 (43%)

10,858 (30%)

4,769 (22%)

21,843 (30%)

 No

7,172 (50%)

21,674 (61%)

7,525 (34%)

36,371 (51%)

 Unknown

991 (7%)

3,060 (9%)

9,519 (44%)

13,570 (19%)

Diagnosed through screening?

 Yes

269 (2%)

17,101 (48%)

2,143 (10%)

19,513 (27%)

 No

13,786 (96%)

17,877 (50%)

19,138 (88%)

50,801 (71%)

 Unknown

324 (2%)

614 (2%)

532 (2%)

1,470 (2%)

ER status

 Positive

10,505 (73%)

28,385 (80%)

16,113 (74%)

55,003 (77%)

 Negative

3,188 (22%)

5,655 (16%)

2,855 (13%)

11,698 (16%)

 Unknown

686 (5%)

1,552 (4%)

2,845 (13%)

5,083 (7%)

PR status*

 Positive

3,096 (51%)

8,471 (53%)

4,499 (50%)

16,066 (51%)

 Negative

1,482 (25%)

3,482 (22%)

1,868 (21%)

6,832 (22%)

 Unknown

1,458 (24%)

3,997 (25%)

2,612 (29%)

8,067 (26%)

HER2 status*

 Positive

1,142 (19%)

2,082 (13%)

981 (11%)

4,205 (14%)

 Negative

4,466 (74%)

12,337 (77%)

6,571 (73%)

23,374 (75%)

 Unknown

428 (7%)

1,531 (10%)

1,427 (16%)

3,386 (11%)

Molecular subtype*

 Luminal A

2,337 (39%)

8,464 (53%)

4,623 (51%)

15,424 (50%)

 Luminal B

2,147 (36%)

3,888 (24%)

1,893 (21%)

7,928 (26%)

 HER2-enriched

310 (5%)

654 (4%)

321 (4%)

1,285 (4%)

 TNBC

802 (13%)

1,388 (9%)

705 (8%)

2,895 (9%)

 Unknown

440 (7%)

1,556 (10%)

1,437 (16%)

3,433 (11%)

Surgery

 Yes

13,753 (96%)

33,509 (94%)

13,099 (60%)

60,361 (84%)

 No

527 (4%)

1917 (5%)

8,389 (38%)

10,833 (15%)

 Unknown

99 (< 1%)

166 (< 1%)

325 (2%)

590 (< 1%)

Radiotherapy

 Yes

9,906 (69%)

24,164 (68%)

7,674 (35%)

41,744 (58%)

 No

3,738 (26%)

9,842 (28%)

13,221 (61%)

26,801 (37%)

 Unknown

735 (5%)

1,586 (4%)

918 (4%)

3,239 (5%)

Chemotherapy

 Yes

10,539 (73%)

14,180 (40%)

1,757 (8%)

26,476 (37%)

 No

3,574 (25%)

20,622 (58%)

19,332 (89%)

43,528 (61%)

 Unknown

266 (2%)

790 (2%)

724 (3%)

1,780 (2%)

Hormone therapy

 Yes

9,298 (65%)

25,953 (73%)

16,671 (76%)

51,922 (72%)

 No

4,065 (28%)

7,583 (21%)

3,971 (18%)

15,619 (22%)

 Unknown

1,016 (7%)

2,056 (6%)

1,171 (5%)

4,243 (6%)

Neoadjuvant therapy

 Yes

11,562 (80%)

31,948 (90%)

20,025 (92%)

63,535 (88%)

 No

2,817 (20%)

3,644 (10%)

1,788 (8%)

8,249 (12%)

Vital status at the end of follow-up

 Dead

3,213 (22%)

8,894 (25%)

14,173 (65%)

26,280 (37%)

 Alive

11,166 (78%)

26,698 (75%)

7,640 (35%)

45,504 (63%)

Breast cancer death^

 Yes

2,748 (86%)

5,095 (57%)

6,139 (43%)

13,982 (53%)

 No

465 (14%)

3,799 (43%)

8,034 (57%)

12,298 (47%)